Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY3546828 in Advanced Metastatic Castration-Resistant Prostate Cancer
NCT06052306Phase 1Active, not recruiting
- Sponsor
- Bayer
- Start
- Sep 2023
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of actinium-225-macropa-pelgifatamab in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by Bayer. Primary endpoints: Incidence of treatment-emergent adverse events, Severity of treatment-emergent adverse events and 4 more. Started Sep 2023; status: active, not recruiting.
02
Drugs
actinium-225-macropa-pelgifatamab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06052306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06052306.